379 related articles for article (PubMed ID: 29754585)
1. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
4. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
5. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
Fernández A
Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
[TBL] [Abstract][Full Text] [Related]
6. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
Yu Y
Front Med; 2018 Apr; 12(2):229-235. PubMed ID: 29209918
[TBL] [Abstract][Full Text] [Related]
8. First Tissue-Agnostic Drug Approval Issued.
Cancer Discov; 2017 Jul; 7(7):656. PubMed ID: 28583911
[TBL] [Abstract][Full Text] [Related]
9. When biomarkers define a drug indication.
Jørgensen JT
Expert Rev Mol Diagn; 2018 Apr; 18(4):315-317. PubMed ID: 29333885
[No Abstract] [Full Text] [Related]
10. Dostarlimab: First Approval.
Markham A
Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
[TBL] [Abstract][Full Text] [Related]
11. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V; Kaestner V; Mailankody S
JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
[No Abstract] [Full Text] [Related]
12. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.
Marcus L; Fashoyin-Aje LA; Donoghue M; Yuan M; Rodriguez L; Gallagher PS; Philip R; Ghosh S; Theoret MR; Beaver JA; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Sep; 27(17):4685-4689. PubMed ID: 34083238
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
